文献速递免疫规划传染病防控与疫情报告

从两项大型III期研究估计疫苗效力和登革热传播相关参数

Estimation of parameters related to vaccine efficacy and dengue transmission from two large phase III studies.
PubMed 文献 · Vaccine · 2015-11-21

基于在亚洲和拉丁美洲五国开展的两项III期登革热疫苗效力研究数据,采用序贯蒙特卡洛方法和队列版传播模型估计登革热传播模型的关键参数,识别出两个参考情景,并模拟疫苗效力随时间演变及20年登革热风险下降幅度。

要点

  • 两个参考情景:一是临时交叉保护,二是合并交叉保护与交叉增强。
  • 疫苗效力因血清型、既往暴露和疾病严重程度而异,且随剂次增加而升高。
  • 20年登革热风险中位下降幅度因国家而异,第一情景为24%至47%,第二情景为34%至54%。

核心结论

  • 本研究是推导结合疾病动力学和疫苗保护机制的通用框架的重要第一步,该框架可用于评估疫苗接种在人群层面的影响。

研究设计与样本

  • 基于两项在亚洲和拉丁美洲五国开展的III期登革热疫苗效力研究数据,采用序贯蒙特卡洛方法和队列版传播模型进行参数估计。

主要发现

  • 识别出两个参考情景:第一情景包含临时交叉保护,第二情景合并了野型感染和接种后的交叉保护与交叉增强。
  • 两个情景均显示疫苗效力因血清型而异,对既往暴露者效力更高,对重症登革热效力更高,对未暴露者效力随剂次增加而升高,且未暴露者的疫苗保护衰减比既往暴露者更明显。
  • 20年内疫苗直接保护所致登革热风险中位下降幅度:第一情景各国为24%至47%,第二情景各国为34%至54%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: A tetravalent dengue vaccine was shown to be efficacious against symptomatic dengue in two phase III efficacy studies performed in five Asian and five Latin American countries. The objective here was to estimate key parameters of a dengue transmission model using the data collected during these studies. METHODS: Parameter estimation was based on a Sequential Monte Carlo approach and used a cohort version of the transmission model. Serotype-specific basic reproduction numbers were derived for each country. Parameters related to serotype interactions included duration of cross-protection and level of cross-enhancement characterized by differences in symptomaticity for primary, secondary and post-secondary infections. We tested several vaccine efficacy profiles and simulated the evolution of vaccine efficacy over time for the scenarios providing the best fit to the data. RESULTS: Two reference scenarios were identified. The first included temporary cross-protection and the second combined cross-protection and cross-enhancement upon wild-type infection and following vaccination. Both scenarios were associated with differences in efficacy by serotype, higher efficacy for pre-exposed subjects and against severe dengue, increase in efficacy with doses for naïve subjects and by a more important waning of vaccine protection for subjects when naïve than when pre-exposed. Over 20 years, the median reduction of dengue risk induced by the direct protection conferred by the vaccine ranged from 24% to 47% according to country for the first scenario and from 34% to 54% for the second. CONCLUSION: Our study is an important first step in deriving a general framework that combines disease dynamics and mechanisms of vaccine protection that could be used to assess the impact of vaccination at a population level.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Coudeville L, Baurin N, Vergu E, et al. Estimation of parameters related to vaccine efficacy and dengue transmission from two large phase III studies. Vaccine. 2015. PMID: 26614588. doi:10.1016/j.vaccine.2015.11.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。